The Russian HIV vaccine “CombiHIVvac”, which was created by specialists from the “Vector” scientific center, turned out to be effective in producing antibodies against the deadly virus and is safe for patients. Experts came to this conclusion after testing the vaccine on volunteers. This was reported by “Interfax” with reference to the press service of the center.
According to scientists, antibodies in HIV and cytotoxic T-lymphocytes after two doses of the vaccine were observed in one hundred percent of the volunteers, and in 80 percent – antibodies that eliminate HIV pseudoviruses. Pseudoviruses are modified viral particles that are identical to pathogenic viruses, but are biologically safe. In addition, the safety of the vaccine for humans has been confirmed.
Clinical studies of CombiHIVvac will continue until the end of 2021. The prophylactic vaccine targets several key HIV proteins that are roughly the same across the three virus subtypes. The drug must prevent the reproduction of the pathogen in the vaccinated person before the virus can “hack” the cells and insert its genes into their genome.